Hypertrophic Cardiomyopathy: Genetics, Mechanisms and Therapies

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Cardiovascular Clinical Research".

Deadline for manuscript submissions: 4 July 2026 | Viewed by 1063

Special Issue Editors


E-Mail Website
Guest Editor
Columbia University Irving Medical Center, Columbia University, New York, NY, USA
Interests: hypertrophic cardiomyopathy; clinical trials; cardiac myosin inhibitors; echocardiography; septal myectomy outcomes

E-Mail Website
Guest Editor
Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
Interests: hypertrophic cardiomyopathy; clinical trials; cardiac myosin inhibitors; echocardiography; proteomics

Special Issue Information

Dear Colleagues,

The Journal of Cardiovascular Development and Disease is launching a Special Issue titled “Hypertrophic Cardiomyopathy: Genetics, Mechanisms and Therapies”. We are privileged to be caring for patients with hypertrophic cardiomyopathy (HCM) and to be studying this condition during a period of remarkable progress in both clinical management and scientific understanding.

Advances in precise genetic diagnostics, improvements in imaging, and the development of targeted medical therapies, including cardiac myosin inhibitors and emerging gene therapies, are transforming the landscape of HCM care. These innovations not only improve symptoms but also hold promise for altering the course of disease. Continued progress in risk stratification, including the growing role of artificial intelligence, is further refining clinical decision-making. Important developments are also underway in the management of atrial fibrillation and heart failure in the context of HCM.

For this Special Issue, we invite you to submit your original research articles and reviews. The aim is to provide a clear and comprehensive update on advances in HCM, encompassing mechanistic insights and contemporary approaches to diagnosis and management.

We look forward to receiving your contributions.

Dr. Shepard D. Weiner
Dr. Lusha W. Liang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • obstructive hypertrophic cardiomyopathy
  • non-obstructive hypertrophic cardiomyopathy
  • treatment, including cardiac myosin inhibitors
  • advanced imaging
  • sudden death risk stratification
  • atrial fibrillation
  • heart failure
  • artificial intelligence
  • genetics and family screening
  • exercise considerations

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 298 KB  
Review
Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy
by Benedetto Ferraresi, Antonio Nenna, Mohamad Jawabra, Diletta Corrado, Andrea Faggiano, Stefano Carugo, Carmelo Dominici, Giovanni Casali, Massimo Chello and Mario Lusini
J. Cardiovasc. Dev. Dis. 2026, 13(5), 187; https://doi.org/10.3390/jcdd13050187 - 29 Apr 2026
Viewed by 734
Abstract
The management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten. Unlike traditional pharmacotherapy, which primarily addresses symptoms, CMIs target the underlying mechanism of sarcomeric hypercontractility, offering significant reductions in left [...] Read more.
The management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten. Unlike traditional pharmacotherapy, which primarily addresses symptoms, CMIs target the underlying mechanism of sarcomeric hypercontractility, offering significant reductions in left ventricular outflow tract (LVOT) gradients and improved functional capacity. This review evaluates the evolving role of CMIs in refining surgical candidate selection and postoperative care. Clinically, CMIs function as an in vivo “biological test” to distinguish between dynamic, functional obstruction—often manageable with medication—and fixed anatomical obstruction driven by complex septal or mitral substrates. While clinical trials demonstrate that CMIs can delay or prevent the need for SRT in a significant proportion of patients, surgery remains the definitive solution for those with dominant structural anomalies or drug intolerance. Consequently, the therapeutic paradigm is shifting from a binary “drugs or surgery” approach to a synergistic model. In this framework, CMIs optimize the identification of patients truly requiring structural myectomy while serving as a valuable adjunct for managing residual hypercontractility, ultimately facilitating a personalized, multidisciplinary approach to HCM treatment. Full article
(This article belongs to the Special Issue Hypertrophic Cardiomyopathy: Genetics, Mechanisms and Therapies)
Show Figures

Graphical abstract

Back to TopTop